Profusa (NASDAQ:PFSA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Profusa (NASDAQ:PFSA) from a strong sell rating to a sell rating in a research note released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Profusa Trading Down 5.3%

Shares of NASDAQ PFSA opened at $0.66 on Friday. Profusa has a 52 week low of $0.41 and a 52 week high of $180.00. The business has a 50-day moving average of $1.10. The company has a market cap of $890,800.00, a P/E ratio of 0.00 and a beta of 0.28.

Profusa (NASDAQ:PFSA) last issued its earnings results on Wednesday, April 15th. The company reported $89.25 EPS for the quarter.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.